Trial Profile
A Phase 3, Randomized, Active-controlled, Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine Given With Dtap Compared To Open-label Dtap In Healthy Japanese Infants
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Dec 2018
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; DTaP vaccine; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Diphtheria; Pertussis; Pneumococcal infections; Tetanus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Pfizer
- 13 Feb 2012 Actual patient number added 551 according to ClinicalTrials.gov.
- 13 Feb 2012 Actual end date (November 2011) added as reported by ClinicalTrials.gov.
- 13 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.